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a  b  s  t  r  a  c  t
We  critically  examine  the discussion  on  the role  of  evidence-based  medicine  (EBM)  in  healthcare  gov-
ernance.  We  take  the  institutionally  layered  Dutch  healthcare  system  as  our  case  study.  Here,  different
actors  are  involved  in  the regulation,  provision  and  financing  of  healthcare  services.  Over  the last  decades,
these actors  have  related  to EBM  to inform  their  actor  specific  roles.  At the  same  time,  EBM  has  increas-
ingly  been  problematised.  To  better  understand  this  problematisation,  we  organised  focus  groups  and
interviews.  We  noticed  that  particularly  EBM’s  reductionist  epistemology  and  its uncritical  use  by  ‘profes-
sional  others’  are  considered  problematic.  However,  our  analysis  also  reveals  that  something  else  seems
to be  at stake.  In  fact,  all the  actors  involved  underwrite  EBM’s  reductionist  epistemology  and  emphasise
that  evidence  should  be  contextualised.  They  however  do  so in different  ways  and  with  different  contexts
in  mind.  Moreover,  the  ways  in which  some  actors  contextualise  evidence  has  consequences  for  the  ways
in which  others  can  do the same.  We  therefore  emphasise  that behind  EBM’s  scientific  problematisation
lurks  a political  issue.  A dispute  over  who  should  contextualise  evidence  how,  in a  layered  healthcare
system  with  interdependent  actors  that  cater  to  both  individual  patients  and  the  public.  We  urge pub-
lic  administration  scholars  and  policymakers  to open-up  the  political  confrontation  between  healthcare
actors  and  their  sometimes  irreconcilable,  yet  evidence-informed  perspectives.













In many countries, ‘evidence-based medicine’ (EBM) has
become an important principle in healthcare governance [1]. It
emerged in the field of clinical epidemiology and gained promi-
nence amongst professionals in the 1990’s [2]. EBM aimed to reduce
unexplained variation in the provision of care. It advocated treat-
ment based on the best epidemiological evidence available [1]
and criticised healthcare decision-making based on professional
authority. It encouraged more standardised forms of decision-
making, based on statistical evidence about the effectiveness of
interventions. EBM furthered randomised controlled trials (RCT’s)
as the gold standard of evidence [3].
The standardising qualities of EBM are increasingly problema-
tised [4]. In the academic literature, EBM is criticised along two
∗ Corresponding author.








0168-8510/© 2020 The Author(s). Published by Elsevier B.V. This is an open access article(http://creativecommons.org/licenses/by/4.0/).
ines of argumentation. Firstly, authors criticise its epistemologi-
al reductionist approach and complex methodology; emphasising
hat EBM draws predominantly on statistical data derived from
elective populations, analysed in ways that only methodological
xperts understand [5]. Secondly, authors criticise its use in – and
eyond – the counselling room. Their critique is that professionals,
ealthcare managers, policymakers, health insurers and regula-
ors base their treatment plans, policies or monitoring instruments
n statistical data, without considering the situation of individual
atients [4,6].
The questioning of EBM’s scientific principles and uncritical
se have become laden affairs in hospitals, knowledge centres,
nsurance companies and government offices. Actors defending
vidence-based healthcare decision-making are classified as ortho-
ox positivists ([7] [responses]). Actors questioning the dominant
ole of statistical evidence in healthcare decision-making are
ccused of quackery [7]. At conferences, the vices and virtues
f EBM are celebrated and disqualified. Presenters are lauded
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or hooted (personal observations 2017). The EBM discussion has
become a site of pluralism, conflict and strive [8].
We argue that a political analysis of the discussion generates
insights that cannot be captured by biomedical or professional
approaches. Informed by Mouffe [8] and Bacchi [9], we conceptu-
alise contemporary healthcare systems as highly political. On the
one hand, such systems consist of different regulatory frameworks
(from professional self-regulation to regulated markets [10,11]).
On the other hand, such systems harbour a plurality of actors [12].
These actors can (re)shape and legitimise actors-specific roles and
positions by relating to different regulatory frameworks and sci-
entific truth claims at different times and for different reasons
[13–15]. Problematising regulatory frameworks and scientific truth
claims can therefore go hand in hand with attempts to improve spe-
cific roles and positions, possibly at the cost of others [16]. A striking
example is the establishment of a division between ‘us’ critical
interpreters of evidence versus ‘them’ naïve users of evidence [8]
and the question who has more legitimacy to make healthcare deci-
sions [13]. In this light, it is important to look beyond the problem
itself and study strategic relations that have gone into a problem’s
making [9].
Informed by the above, we examine: a) how EBM informs the
identities, roles and positions of different actors in layered health-
care systems; and b) the perceived problems that emerge from such
differences when it comes to healthcare decision-making. We do
so by answering the following research question:
How and by whom has the role of EBM in healthcare decision-
making been problematised and why is that the case?
The Netherlands has become an exemplary case to reveal the
complex relations in which EBM has become constituted as a
problem that needs to be solved. Here, healthcare governance,
traditionally controlled by professional authority, has been sup-
plemented with a plethora of market and state-based regulatory
arrangements [10]. In doing so, the Dutch case resonates with the
healthcare systems in many Western countries [1,17].
Our political analysis reveals that behind the epistemologically
and professionally framed discussion unfolds a dispute over who is
able – and should be allowed – to interpret and contextualise clin-
ical epidemiological evidence in decision-making that does right
to individual patients and upholds the quality, safety and afford-
ability of a collective healthcare system. The future of EBM should
therefore not just be an epidemiological or professional project.
Instead, we urge policymakers and scholars of public administra-
tion to take the EBM discussion seriously and to start focusing on
the layered healthcare systems in which evidence-informed deci-
sions are being made.
2. EBM in the layered Dutch healthcare system
As in many Western countries, the dominant position of Dutch
healthcare professionals has been called into question [18]. EBM
played an important role in this process as it scrutinised healthcare
decision-making based on professional authority and stimulated
decision-making based on the best evidence available [2]. The
early advocates of EBM however still intended for evidence-based
decision-making to be a professional affair; describing it as a pro-
cess of critical appraisal [4]. Critical appraisal here referred to the
use of: (a) clinical epidemiological evidence, (b) clinical experience
and (c) patients’ needs and wishes, during shared decision-making
with patients in the counselling room [2].However, Dutch healthcare governance was changing beyond
the convinces of professional self- regulation. As new governance
principles such as ‘accountability’, ‘efficiency’ and ‘affordability’
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egulatory arrangements introduced on top of professional self-
egulation. A Dutch example is the introduction of the Health
nsurance Act in 2006 [19]. This act aimed to reduce costs and raise
he quality of healthcare through the introduction of market mech-
nisms. It decreed that professionals should start competing on the
uality and price of healthcare services. Concurrently, it strength-
ned the position of health insurers. They should start negotiating
ith providers about the price, volume and quality of healthcare
rovided.
Meanwhile, the Dutch healthcare system was not entirely left to
he whims of the market. In addition, several semi-governmental
rganisations were charged with safeguarding access to care and
inimum quality [10]. The Dutch Healthcare Institute was, for
nstance, charged with stimulating and overseeing the develop-
ent of quality instruments and with advising the Minister of
ealth on which care should be included in and excluded from
he ‘basic healthcare agreement’. This agreement recognises the
inimum care to be covered by health insurers; thereby making
uch care accessible for (obligatory insured) Dutch citizens. More-
ver, the Dutch Healthcare Inspectorate continued to inspect on
he quality and safety of care provided.
By introducing market mechanisms beside professional self-
egulation and state-based regulation, a layered healthcare system
merged [10]. An effect of such layering is that healthcare decision-
aking has become fragmented [11]. It prompted a proliferation of
professional others’ involved in healthcare decision-making [12].
xamples are health insurers, policymakers, knowledge institutes
nd inspectorates. Each of these actors has adopted EBM in the
ays in which they shape their roles and legitimise role-specific
ecisions [9,13,14]. But, as we  will also show in of our empirical
ection, this wide uptake of EBM has not brought coherence in the
overnance of care (Fig. 1).
. Materials and methods
Our inquiry stems from a discussion in the Netherlands about
vidence-based decision-making. In fact, the first and third author
articipated as researchers in a Dutch advisory board (de Raad
oor de Volksgezondheid and Samenleving [RVenS]) that sought
o better understand the implications of this discussion for Dutch
ealthcare governance [20]. Data gathered for the policy advice
s reused in this paper. Although the problems presented below
eflect the policy advice, we have placed more emphasis on a polit-
cal analysis of EBM’s problematisation [9].
To gain insight into the Dutch discussion, the RVenS organ-
sed two focus groups in November and December 2016. The first
ncluded a variety of experts (N = 7); medical sociologists, a medical
istory scholar and a medical philosopher, studying and publish-
ng on EBM. The second included healthcare practitioners from the
eld (N = 5); a medical specialist, a general practitioner, a geriatric
ractitioner, a medical researcher and a junior medical specialist.
o gain complementary insight, the RVenS organised interviews in
he spring of 2017. Interviewees were a psychiatrist (N = 1); gynae-
ologists (N = 2); midwife (N = 1); respondents from the Dutch
ealthcare Inspectorate (N = 2); a knowledge institute (N = 5); and
 healthcare insurer (N = 2).
With our sampling approach, we aimed to gain insight into the
ifferent ways in which EBM was  problematised and/or defended
nd why  it was problematised or defended as such. Informed by
acchi [9], we  therefore approached respondents that were: a)
ctively involved in the discussion; and b) represented different
inds of actors in Dutch healthcare governance. Importantly, our
im was  not to work towards a representative sample of one of
hese actor groups specifically (e.g. a specific group of medical spe-
ialists), or the Dutch healthcare system as a whole (with all the













Fig. 1. A representation of the layered Dutch h
different actor groups included). Instead, our aim was to identify
those actors – and their interrelations – through which EBM had
become constituted as a problem that needed to be solved. We
reflect on the limitations of this approach at the end of our dis-
cussion.
Focus groups and interviews were semi-structured around two
questions: I) how does EBM contribute to healthcare provision?
and II) which problems or challenges do respondents encounter?
Focus groups and all but one of the interviews were audiotaped
and transcribed verbatim. Where audiotaping was  not possible,
fieldnotes were made and further elaborated afterwards. Individual
contributions were anonymised.
For this paper, we revisited the transcripts. We  coded passages
of what EBM is (and what not), what its problems are (and what
not) and how it should be used by who (and who not). We  member-
checked our analysis on two separate occasions in the spring of
2017. We  presented our preliminary interpretation on a conference
on evidence-based guideline development and during the public
release of the policy advice [20]. Comments were used to fine-tune
our analysis.
4. Results: the problems of EBM in the Dutch governance of
careThis empirical section is divided into three parts. First, we
present how EBM informs the actions of actors in Dutch health-
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as become problematised. Lastly, we consider how these prob-
ematisations mirror decision-making dynamics between actors in
he layered Dutch healthcare system.
Part 1: the use of EBM by different actors
Each of the actors introduced in Fig. 1 uses EBM in and on their
wn  terms. In the coming four subsections, we describe how.
.1. Evidence in the counselling room
The professionals we  interviewed described themselves as
nterpreters who  make context dependent decisions about individ-
al treatment plans. Such treatment plans are informed by clinical
pidemiological evidence, but they cannot be reduced to such evi-
ence. In fact, the interviewed professionals stressed that they
hould be able to translate evidence to the health problem of indi-
idual patients.
‘The whole idea is that you explore the problem of the patient
in the context of the patient, then look into what the [evidence-
informed] guidelines say about what we do – on average – with
such a problem and after that make a decision together with the
patient.’ (Geriatric practitioner, focus group, 2016)
We observed that the way  professionals describe their own
ractice strongly resembles Greenhalgh et al. [4] celebration of
n original form of EBM [2]. One thing is different though. There
here Sackett et al. [2] emphasised the critical appraisal of the best
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evidence-informed professional guidelines. In the next paragraph,
we explain why this is an important difference.
4.2. Evidence in guideline development
Although professionals frequently refer to professional guide-
lines when talking about evidence, such guidelines are more than a
representation of clinical epidemiological evidence. In fact, not only
in the counselling room, but also in the development of guidelines,
such evidence is weighted next to clinical experience and patients’
needs and wishes.
‘Guidelines are supported by evidence, but they also include a trans-
lation of the international evidence to the Dutch context, the extent
of the problem here, its specific organisation of care, the patient
perspective. Only after that do we present considerations and rec-
ommendations.’ (Gynaecologist, interview, 2017)
Although the relative weight of the patient perspective remains
an important point for discussion [21], the abovementioned quote
illustrates how professional guidelines claim to be more than a sum
of the epidemiological evidence on a topic. In fact, what emerges is
a situation in which evidence is contextualised on two  levels within
a professional context: in the development of guidelines and in the
counselling room.
4.3. Evidence in regulating quality and safety
Next to professionals, other actors use professional guidelines
to inform their actions. For instance, the Dutch Healthcare Inspec-
torate uses the developed guidelines to: (a) prospectively influence
healthcare processes; and (b) to retrospectively assess the safety
and quality of care provided (Inspector, interview, 2017).
According to the Inspectorate, the content of care is still in the
hands of professional organisations through their key role in guide-
line development. The Inspectorate, in turn, supervises whether
professionals live up to the standards that professionals set for
themselves in these guidelines. In the words of an inspector (inter-
view, 2017):
‘There is no evidence that driving on the right side is safer than
driving on the left side. Nevertheless, there is enough evidence that
supports the idea that a decision needs to be made to either drive
on the left or on the right side of the road.’
The Inspectorate acknowledges the weighing of evidence on the
level of guideline development. At the same time and in contrast
to the first subsection, the Inspectorate’s approach compromises
the critical appraisal of such guidelines in the counselling room. To
be specific here, the Inspectorate supports the professional’s claim
that clinical epidemiological evidence needs to be contextualised.
The Inspectorate however also emphasises that such contextuali-
sation should be done uniformly and on an aggregate level; that of
the professional organisation.
4.4. Evidence in policymaking
Also the Dutch Healthcare Institute uses clinical epidemiological
evidence and professional guidelines. They do so to provide policy
advice to the Ministry of Health about which treatments should
be (preliminary) included in the ‘basic healthcare agreement’. This
agreement dictates which care is to be considered standard insured
care and needs to be covered by health insurers. The Institute’s
objective is to include care that is proven effective and affordable
in order to protect a healthcare system that is collectively financed
[22].
The Institute developed a systematic assessment framework to
support them in their task [22]. Relative effectiveness is the key
37Health Policy 125 (2021) 34–40
rinciple in this framework. This means a treatment needs to be
n improvement, this improvement needs to be significant, and it
hould exert itself in professional practice [22]. It is here that pro-
essional and patient perspectives are considered, specifically there
ere evidence is inconsistent or where there is broad consensus
bout value of treatment [22].
In following these steps, the Dutch Healthcare Institute explic-
tly relates their actions to the principles of EBM.
‘We use the principles of EBM in our assessment. Although it was
developed to aid professionals to make clinical decisions for individ-
ual patients, its principles have found a much broader application.
It is also used in the development of professional guidelines and
policies regarding public health. In these cases, it is no longer about
decision-making in relation to individual patients, but rather about
advice and decisions on the level of the population.’ ([22]: 6)
The Institute uses EBM’s methodological design on how to
ather and grade evidence [3], but explicitly departs from [2]
mphasis on weighing such evidence in the context of individual
atients. Instead, they weigh such evidence in the context of the
utch population. Although professional insights and the patient
erspective are considered, the Institute makes evidence-based
ssessments independent from the professional organisations.
.5. Concluding remarks for part 1
All actors presented above legitimise their roles and decisions by
elating to clinical epidemiological evidence. Each of them further-
ore stresses the importance of contextualising evidence. They do
o on different levels and in line with their perceived roles. Individ-
al professionals contextualise evidence in the counselling room
n relation to individual patients; professional organisations (and
he Dutch Healthcare Inspectorate) do so on the level of guidelines
evelopment in relation to patient groups; and the Dutch Health-
are Institute does so in policymaking in relation to the Dutch
opulation.
Part 2: EBM’s problematisation
In this subsection, we  present the main problems identified in
he Dutch EBM discussion. We  emphasise at the onset that it is
ainly professionals who voice problems. Below, we discuss these
n turn.
.6. The biddable use of guidelines
A problem frequently voiced by professionals is about other
rofessionals. It addresses the way  in which evidence-informed
uidelines are used in the counselling room:
‘Guidelines should provide support in the counselling room, but
often they are used as key stones. You receive a patient with hyper-
tension and check the guideline for treatment. A second question
could then be “who is actually sitting in front of me?” But often,
doctors don’t do that.’ (Internist, interview, 2016)
These professionals stress the importance of weighing clinical
pidemiological evidence next to clinical experience and patients’
eeds and wishes, but conclude that there is a lack of it in the
ounselling room. This is a longstanding problematisation of EBM,
requently addressed in the literature as well [23].
Importantly, those that address this problem relate such uncrit-
cal use of guidelines to forces external to individual professionals
nd their actions in the counselling room. A junior medical special-
st tries to describe the cause of this problem:‘It is a kind of defensive medicine; because others can hardly ques-
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This professional articulates uncertainty amongst professionals.
A form of uncertainty that constrains them to critically interpret –
and where necessary divert from – guidelines in decision-making
with and for individual patients.
4.7. Weighing evidence on the right level
We  previously observed that professional organisations consid-
ered their guidelines as uniform agreements amongst professionals
about how to treat patients. Guidelines are therefore informed
by clinical epidemiological evidence, clinical experience and the
patient perspective. Guidelines are thus much more than represen-
tations of clinical epidemiological evidence alone. Yet it is exactly
this weighing of evidence on the level of guideline development
that is problematised by professionals we interviewed.
‘When something is proven effective, then there is no problem in
presenting that in guidelines [and considering that a uniform agree-
ment]. The problem however is that many things in guidelines are
based on consensus or authority. In those cases, I feel it is harder to
divert from the guideline.’ (Gynaecologist, interview, 2016)
There where the guideline is based on consensus – or a
weighted interpretation of evidence – professional organisations
have already included the patient perspective and clinical experi-
ence on an aggregate level. In the counselling room, professionals
subsequently feel that they are expected to follow the weighted
advice. Diverting from the guidelines then no longer means divert-
ing from the clinical epidemiological evidence. Instead, it means
diverting from the agreements that professional organisations, in
collaboration with other actors, have made as a professional col-
lective for individual professionals.
The professionals we interviewed thus feel that weighing and
contextualising is important, but problematise the level on which
that is done. These professionals criticise the emergent trend
in which professional organisations translate evidence, clinical
experience and the patient perspective into general agreements
presented in guidelines (previous subsection). These professionals
argue that guidelines can never capture the complexity of treating
individual patients. They produce a false sense of collective pro-
fessional control over healthcare decision-making and impede the
role of individual professionals; which is to weigh evidence, next
to clinical experience and patients’ needs and wishes, with patients
and in the counselling room.
4.8. The professional other
The fact that ‘professional others’ use professional guidelines
to inform their actor-specific actions further complicates the
situation. Such use is problematised by both professionals and rep-
resentatives of professional organisations that engage in guideline
development.
‘What I find problematic is that many healthcare actors see guide-
lines as “this is the way things need to be done and when you
don’t do it like that it is wrong”. The Inspectorate for instance talks
about norms. In that phrasing already lies a very different meaning
attached to guidelines.’  (Representative of a knowledge institute,
interview, 2016)
‘The problem is that insurers use insights derived from averages of
populations to measure the quality of care delivered to individual
patients.’ (Internist, focus group, 2016)In abovementioned quotes, a precarious tension is articulated
between: (a) the way in which professionals translate professional
guidelines to the context of individual patients; and (b) the way in
which insurers and inspectorates use such guidelines to determine
38Health Policy 125 (2021) 34–40
hether the care that has been provided to individual patients is in
ine with the uniform agreements made. For most interviewed pro-
essionals, it is here that professional guidelines, useful for tinkering
n the treatment for and with individual patients, consolidate into
igid norms.
.9. Concluding remarks part 2
In the discussion on EBM, a distinction is drawn between
he (ideal typical) patient-centred individual professional and
he (problem typical) standardisation-centred professional other.
hether this professional other is a health insurer, health inspec-
orate, or professional organisation does not really matter. What
atters to those that problematise EBM is that clinical epidemio-
ogical evidence is reductionist and needs to be contextualised. At
he same time, the counselling room is furthered as the site where
uch contextualisation should take place. In the next section, we
iscuss why  this line of reasoning needs scrutiny.
Part 3: who decides based on what?
It is important to underline that other actors involved in the
overnance of care do not disagree with healthcare professionals
hat clinical epidemiological evidence needs to be interpreted and
ontextualised. In fact, most actors involved seem to interpret and
ontextualise such evidence themselves, albeit in and on their own
erms (first empirical subsection). The issues raised above therefore
o not seem to be about whether clinical epidemiological evidence
hould be interpreted and contextualised, but rather about who
hould interpret and contextualise such evidence and how.
For most professionals that engage in the EBM discussion, the
uestion who  should interpret clinical epidemiological evidence is
asily answered:
‘Health insurers should not be able to say: “there is no evidence
for this so we do not pay”. We  sit in the counselling room not
them. . . Insurers should not determine, only pay.’ (Gynecologist,
interview, 2017)
In the Netherlands, after the introduction of the Health Insur-
nce Act in 2006, health insurers are formally given the role
o represent their insured (patients) in negotiations with pro-
essionals about the price and quality of care. However, neither
rofessionals nor insurers act as independent negotiators. Pro-
essionals are deemed by inspectorates to live-up to the uniform
greements presented in guidelines developed by professional
rganisations. Insurers are obliged to insure care included in the
basic healthcare agreement’. In this context, evidence-informed
ealthcare decisions are no longer under control of either pro-
essionals, insurers, patients or the state. Instead healthcare
ecision-making has become fragmented and dynamic, influencing
 and being influenced by – actors in different spheres [10].
This creates direct tensions between actors involved about how
o interpret and contextualise clinical epidemiological evidence
nd about the consequences of such interpretations.
‘We just had a discussion with the Dutch Healthcare Institute about
fertility preservation. . . There is this professional guideline that
says it is considered good care when you discuss this and that with
patients and when you decide to freeze an ovary. Putting it back,
however, is considered another treatment. A process for later. So
far, 70 children have been born by a replaced ovary. We  thus see
that it is possible. But the Dutch Healthcare Institute still considers it
experimental [in other words, the clinical epidemiological evidence
for this treatment is not yet conclusive]. Hence, it is not considered
insured care. It feels so wrong that the professional guideline con-
siders it good care, but the Dutch Healthcare Institute does not
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In abovementioned example, the Dutch Healthcare Institute
relates to EBM’s evidence hierarchy in order to make a binary
decision that counts for all Dutch citizens; the exclusion of a treat-
ment from the basic healthcare agreement due to limited and low
graded evidence [24]. Of key concern is that this interpretation
of evidence by the Institute differs from – yet does have conse-
quences for – the evidence-informed actions of professionals in
the counselling room. These professionals want to interpret the
evidence that does exist in the context of an individual patient.
However, this becomes impossible because the basic healthcare
agreement prescribes what insurers should consider insured care.
Professionals, in turn, can hardly recommend treatments that are
not covered by health insurers. In the Dutch governance of care, the
evidence-informed decisions of some actors can thus exclude the
evidence-informed actions of other actors.
It is in response to the above that many professionals problema-
tise EBM’s reductionist epistemology and stress the importance
of contextualising clinical epidemiological evidence. However, we
would like to point out that the problem with EBM in above-
mentioned example is not necessarily a lack of contextualisation.
Rather, the problem is that interdependent actors interpret and
contextualise clinical epidemiological evidence in very different
ways. Professionals interpret such evidence in the context of the
situation of an individual patient; the Dutch Healthcare Insti-
tute interprets such evidence in the context of policymaking on
the level of the Dutch population. Importantly, when clinical epi-
demiological evidence is contextualised on the level of the Dutch
population, such contextualisation is not necessarily a remedy to
EBM’s reductionism. After all, in the latter case, reductions are
placed in the context of other reductions (e.g. ‘general consen-
sus’ or ‘the patient perspective’). As we pointed out previously, this
not only happens on the level of policymaking, but also in guide-
line development and in negotiations between health insurers and
healthcare providers.
5. Discussion
In this paper, we formulated the following research question:
How and by whom has the role of EBM in healthcare decision-
making been problematised and why is that the case? We  took the
Netherlands as our case study. We  observed that EBM informs the
practices of a variety of actors, operating on different levels (Fig. 1).
We furthermore observed that each of these actors underlines the
importance of contextualising clinical epidemiological evidence.
They contextualise such evidence within their own organisations
(from the counselling room to policy offices), according to specific
methodologies (from critical appraisal to systematic assessments)
and in relation to actor specific objectives and responsibilities (from
crafting individual treatment plans to proposing national policies).
We however also observed that in a layered healthcare system, the
contextualisation of evidence by one actor can limit the ways in
which other actors are able to contextualise such evidence. We
argue this is an important reason why EBM has been problema-
tised in Dutch healthcare governance and why a division emerged
between an ‘us professionals and critical interpreters of evidence’
versus ‘them professional others and naïve users of evidence’ [8]. In
this light, the Dutch EBM discussion not only concerns the value of
clinical epidemiological evidence, but also concerns who  should be
considered a legitimate actor to make evidence-informed health-
care decisions [13].Based on the abovementioned observations, we challenge some
dominant claims made in the Dutch EBM discussion, as well as in
the international medical literature. Emphasis is often placed on the
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) that such evidence should therefore always be contextualised
6]; and c) that this no longer happens because professional others
ave adopted EBM uncritically and place constrains on individ-
al professionals to contextualise such evidence in the counselling
oom [4]. The main issue we want to address in this line of reason-
ng has to do with step c. As we revealed, clinical epidemiological
vidence is interpreted and contextualised on different levels, by
ifferent actors and in the context of a great many things; rang-
ng from patients’ individual needs and wishes, to quality and
afety, healthcare expenditures and the protection of a collec-
ively financed healthcare system. Classifying EBM as a reductionist
pproach might thus be epistemologically sound and calling for
ontextualisation might be a logical response. However, such calls
or contextualising are not enough to resolve the current tensions
hat have emerged around evidence-informed decision-making. In
act, most actors agree that EBM is a reductionist approach and that
linical epidemiological evidence needs to be contextualised; but
hey all do so in and on their own terms. The contextualisation of
BM is therefore not absent. Rather, it is all over the place.
Our inquiry into EBM’s problematisation has three important
imitations. Firstly, by focussing on the use of clinical epidemi-
logical evidence in healthcare decision-making, we ignore the
rocess in which such evidence is produced. Different scholars have
owever critically discussed how a plethora of actors participate
n and influence this process (e.g. pharmacists and professional
xperts [26,27]). The clinical epidemiological evidence used in
ealthcare decision-making should therefore not be considered
bsolute, objective or neutral (before the politics of contextualising
28]). Secondly, the actors that feature in this paper do not repre-
ent homogenous groups. Amongst healthcare professionals – and
ithin the healthcare organisations discussed – deliberations exist
bout the ways in which evidence should be interpreted [29]. In the
BM discussion, however, such nuances are often backgrounded
hilst more clear-cut divisions between ‘us’ critical interpreters
ersus ‘them’ naïve users are foregrounded (see also part two of
ur results section). Thirdly, we  base our analysis on respondents
hat actively engaged in the EBM discussion. Therefore, not all
ctors that use EBM in healthcare decision-making are included.
xamples missing are the Dutch Ministry of Health and individual
atients. We chose to focus on those that engaged in the discus-
ion because it allowed us to identify the strategic relations part
nd parcel of EBM’s problematisation [9]. Nevertheless, we  recog-
ise that not participating in the discussion could also be a strategic
hoice. For instance, following the principles of market regulation
nd recognising the complexity of the problem, the Ministry could
ave avoided getting involved, leaving the discussion up to those
hat engage with one another on this regulated healthcare market.
mportant examples are professionals, health insurers and those
emi-governmental organisations overseeing their conduct (Fig. 1).
t is interesting to consider such strategies of non-engagement in
uture studies into the politics behind EBM’s problematisation.
Comparative analyses are another interesting direction to
urther explore EBM’s problematisation and a politics of contextu-
lising clinical epidemiological evidence. Many Western healthcare
ystems consist of layered regulatory frameworks [10] and a
lethora of interdependent actors that relate to such frameworks
s well as EBM [12]. In most of these systems, EBM has been prob-
ematised [1,4,17]. In this light, it is important to assess whether and
ow a politics of contextualising exists in these systems and the
onsequences this has for actor-relations and evidence-informed
ecision-making. Such insights are important, we argue, because
hey will deepen our understanding of system specific relations
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6. Conclusions
EBM is particularly problematised in a medical and scientific
register. However, we argue that the discussion is actually fuelled
by: I) tensions between individual and public needs; II) the layer-
ing of institutional arrangements that have been introduced to deal
with such tensions; and III) the differences between actors and their
idiosyncratic roles and positions presumed and legitimised by such
layered arrangements as well as clinical epidemiological evidence
[10,11]. This makes the EBM discussion not just a professional affair,
but rather a question of governance. We  therefore urge policymak-
ers and public administration scholars to take the EBM discussion
seriously and to start scrutinising the layering of healthcare sys-
tems and the ways in which such layers shape evidence-informed
healthcare decision-making. We  furthermore urge healthcare pro-
fessionals to take the EBM discussion beyond their counselling
rooms and open-up to a broader discussion about the role of clinical
epidemiological evidence in layered healthcare systems [1,17].
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